Logo

Regeneron and Sanofi Announces Acceptance of sBLA for PRALUENT's by the US for the Treatment of Reduction in MACE

Share this

Regeneron and Sanofi Announces Acceptance of sBLA for PRALUENT's by the US for the Treatment of Reduction in MACE

Shots:

  • Results of P-III ODYSSEY OUTCOMES assessing PRALUENT(alirocumab) IV (N= 18-924)- having an acute coronary syndrome (ACS)- such as a heart attack- b/w 1-12 mos before being enrolled
  • The US FDA has set a PDUFA date of 28 April- 2019. ODYSSEY OUTCOMES demonstrated a reduction in overall risk of MACE
  • Additionally- FDA updated Praluent PI for the treatment of heterozygous familial hypercholesterolemia (HeFH) in patients with recommended dose of 150 mg q2w
  • Praluent (a PCSK9i) was developed by Regeneron and Sanofi using Regeneron’s VelocImmune technology- and is being approved in >60 countries (incl. the US- Japan- Canada- Switzerland- Mexico and Brazil and EU)

/ article | Ref: Regeneron | Image: Foursquare


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions